WEBThe TiNivo-2 clinical trial was designed to evaluate the benet of adding nivolumab, a PD-1 checkpoint inhibitor, to low dose FOTIVDA versus standard dose FOTIVDA in the second-line following ICI combinations or the third-line setting following prior ICI.
Tivozanib Outperforms ICI Combo in Advanced RCC
WEB2 days ago · The TiNivo-2 trial (NCT04987203) investigated the efficacy and safety of combining the PD-1 inhibitor nivolumab (Opdivo) with the selective VEGFR TKI tivozanib (Fotvida) in patients with advanced clear-cell renal cell carcinoma who had progressed on prior checkpoint inhibitor-based therapy.
Fotivda Shows Better Outcomes Than Combo in Metastatic Kidney …
WEB2 days ago · Findings were based on the phase 3 TiNivo-2 study and presented at the 2024 ESMO Congress. Study highlights: Patients with metastatic renal cell carcinoma (RCC) who received Opdivo and Fotivda after experiencing disease worsening on a PD-(L)1 inhibitor did not experience improved outcomes.
AVEO Oncology, an LG Chem company, Announces Acceptance of …
WEBSep 3, 2024 · The oral presentation will announce the results from the TiNivo-2 clinical trial, which was designed to evaluate the benefit of adding nivolumab, a PD-1 checkpoint inhibitor, to low dose...
WEBBOSTON, Sept. 3, 2024 /PRNewswire/ -- AVEO Oncology, an LG Chem company ("AVEO"), announced today their late-breaking abstract detailing their Phase 3 TiNivo-2 trial has been selected as a Pro ered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain this September 13-17 th .
Tivozanib plus nivolumab versus tivozanib monotherapy in …
WEBSep 13, 2024 · TiNivo-2 is the second prospective, randomised, phase 3 study showing that ICI rechallenge in metastatic renal cell carcinoma does not improve outcomes and should be avoided. In addition, this study showed that neither treatment sequence of ICI rechallenge following an ICI break nor rechallenge with an …
AVEO Oncology, an LG Chem company, Present TiNivo-2 Results …
WEBSep 16, 2024 · The TiNivo-2 clinical trial was designed to evaluate the treatment of FOTIVDA, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in combination with...
TiNivo-2: A phase 3, randomized, controlled, multicenter, open …
WEBFeb 16, 2022 · Methods: TiNivo-2 (NCT04987203) is a phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following 1-2 lines of therapy including an immune checkpoint …
AVEO Oncology Announces Completion of Enrollment in Pivotal …
WEBJun 27, 2023 · The randomized, controlled, open-label TiNivo-2 Phase 3 study enrolled patients with RCC who have progressed following prior immunotherapy treatment. Patients were randomized 1:1 to receive either low dose FOTIVDA in combination with OPDIVO or standard dose FOTIVDA alone.
AVEO Oncology, an LG Chem company, Announces Acceptance of …
WEBSep 3, 2024 · AVEO Oncology, an LG Chem company ("AVEO"), announced today their late-breaking abstract detailing their Phase 3 TiNivo-2 trial has been selected as a Proffered Paper oral presentation at the...